In a separate trial, patients with mild-to-moderate Covid-19 had their risk of developing severe disease reduced by 88 per cent, when one dose of AZD7442 was given within three days of developing symptoms.A
Copyright © 2024 - Odisha Television Limited All Rights Reserved.